# US 2022/0008512 A1 · Anti-cancer monotherapy using sa-4-1bbl

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0008512 A1
- Document ID: US20220008512A1
- Status: Published application
- Kind: A1
- Application number: 17/294,157
- Filed: 2019-11-15
- Published: 2022-01-13
- Earliest claimed: 2018-11-15
- Assignees: University of Louisville Research Foundation, Inc.; Fascure Therapeutics, LLC
- Applicants: University of Louisville Research Foundation, Inc.; Fascure Therapeutics, LLC
- Inventors: Haval SHIRWAN; Esma S. YOLCU; Rajesh SHARM
- Web page: https://patentgrep.com/patent/US20220008512A1

## CPC

- A61K 38/191: {Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/5107: {Excipients; Inactive ingredients}
- A61K 38/164: {from bacteria}
- A61K 38/1709: {from mammals}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein are methods for treating and preventing cancer. In particular, described herein are methods using SA-4-1BBL as a monotherapy agent to treat, prevent or reduce the risk of cancer, treat, prevent, or reduce the risk of tumorigenesis, and treat, prevent, or reduce the risk of post-surgical tumor recurrence. SA-4-1BBL for use as a monotherapy in such methods also is provided.

## Claims

### Claim 1

A monotherapy method of preventing or treating a cancer, comprising administering to a subject in need thereof an effective amount of SA-4-1BBL, wherein the monotherapy method does not include administering to the subject an antigen associated with the cancer.

### Claim 2

A monotherapy method of reducing the risk of tumorigeneses, comprising administering to a subject in need thereof, an effective amount of SA-4-1BBL, wherein the monotherapy method does not include administering to the subject an antigen associated with the tumor.

### Claim 3

A monotherapy method of reducing the risk of tumor recurrence, comprising administering to a subject in need thereof, an effective amount of SA-4-1BBL, wherein the monotherapy method does not include administering to the subject an antigen associated with the tumor.

### Claim 4 (depends on 4)

A method according to claim 4, wherein the subject has undergone surgical removal of tumor cells, chemotherapy, and/or cancer irradiation treatment.

### Claim 5 (depends on 1, 2, 3, 4)

A method according to any one of claims 1-4, wherein the subject is suffering from chronic liver disease, has a hereditary mutation in a p53 gene, has a hereditary mutation in a breast cancer gene, has a DNA repair deficiency, and/or has preneoplastic or early neoplastic lesions.

### Claim 6 (depends on 1, 2, 3, 4)

A method according to any one of claims 1-4, wherein the subject has lifestyle risk factors, environmental risk factors, a history of hereditary BRCA1 and/or BRCA2 mutations, Lynch Syndrome, Cowden Syndrome, and/or is infected with HPV.

### Claim 7 (depends on 1, 2, 3, 4)

A method according to any one of claims 1-4, wherein the SA-4-1-BBL is administered by intravenous, subcutaneous, or intraperitoneal injection.

### Claim 8 (depends on 1, 2, 3, 4)

A method according to any one of claims 1-4, wherein the SA-4-1-BBL is administered twice, two weeks apart.

### Claim 9 (depends on 8)

The method of claim 8, wherein the method further comprises a rest period of 2-6 months, after which the SA-4-1-BBL is administered twice, two weeks apart.

### Claim 10 (depends on 1, 2, 3, 4)

A method according to any one of claims 1-4, wherein the SA-4-1-BBL comprises the amino acid sequence of the extracellular domain of human 4-1-BBL.

### Claim 11 (depends on 1, 2, 3, 4)

A method according to any one of claims 1-4, wherein the SA-4-1-BBL comprises the amino acid sequence set forth in FIG. 8B.

### Claim 12

An SA-4-1-BBL conjugate having the amino acid sequence set forth in FIG. 8A or FIG. 8B.

### Claim 13 (depends on 12)

A composition comprising a SA-4-1-BBL conjugate according to claim 12 and a carrier.

### Claim 14 (depends on 12)

A pharmaceutical composition comprising an SA-4-1-BBL conjugate according to claim 12 and a pharmaceutically acceptable carrier.

### Claim 15 (depends on 14)

A pharmaceutical composition according to claim 14, wherein the pharmaceutically acceptable carrier is suitable for administration by intravenous, subcutaneous, or intraperitoneal injection.

### Claim 16

A SA-4-1BBL conjugate for a monotherapy method for preventing or treating a cancer, reducing the risk of tumorigeneses, and/or reducing the risk of tumor recurrence, wherein the conjugate has the amino acid sequence set forth in FIG. 8A or FIG. 8B, and the monotherapy method does not include administering to the subject an antigen associated with the cancer or tumor.
